dcas9 dnmt3a puror v2 (Addgene inc)
Structured Review
Dcas9 Dnmt3a Puror V2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dcas9+dnmt3a/pdCas9-DNMT3A-PuroR_v2+(Plasmid+%2374407)/bio_rxiv__64898__2026__10__27__762200-447-18-19
Average 93 stars, based on 12 article reviews
Images
Related Articles
Plasmid Preparation:Article Title: Defining Mechanistic Links Between the Non-Coding Variant rs17673553 in CLEC16A and Lupus Susceptibility Article Snippet: .. We co-transfected the guide RNA-containing plasmid (VectorBuilder) along with CRISPRa plasmids dCas9-VPR and dCas9-TET1 (Addgene), and CRISPRi plasmids dCas9-KRAB-MECP2 and Article Title: Defining Mechanistic Links Between the Non-Coding Variant rs17673553 in CLEC16A and Lupus Susceptibility. Article Snippet: .. We co-transfected the guide RNA-containing plasmid (VectorBuilder: Neu-Isenburg, Germany) along with CRISPRa plasmids dCas9-VPR and dCas9-TET1 (Addgene: Watertown, MA, USA), and CRISPRi plasmids dCas9-KRABMECP2 and Article Title: Defining Mechanistic Links Between the Non-Coding Variant rs17673553 in CLEC16A and Lupus Susceptibility Article Snippet: .. We co-transfected the guide RNA-containing plasmid (VectorBuilder: Neu-Isenburg, Germany) along with CRISPRa plasmids dCas9-VPR and dCas9-TET1 (Addgene: Watertown, MA, USA), and CRISPRi plasmids dCas9-KRAB-MECP2 and Article Title: Hypoxia-induced CTCF mediates alternative splicing via coupling chromatin looping and RNA Pol II pause to promote EMT in breast cancer. Article Snippet: The designed sgRNA were cloned into dCas9_DNMT3A (Addgene #74407) expression vectors as described previously40,86 using BpiI/BbsI (Fermentas, Cat No. ER1012). .. Additionally, Addgene #71830 plasmid having non-targeting (NT) control guide RNAs (sgcontrol) was used as a control for Clone Assay:Article Title: Hypoxia-induced CTCF mediates alternative splicing via coupling chromatin looping and RNA Pol II pause to promote EMT in breast cancer. Article Snippet: Next, for rescue experiments, CTCF depleted cells were transfected with COL5A1exon64A or COL5A1exon64B transcript overexpression plasmid using Lipofectamine 2000 reagent (Invitrogen, 11668019) as per the manufacturer’s instructions. sgRNA designing and cloning in dCas9-DNMT3A expression vector and cell transfections GT-Scan web-tool (http://gt-scan.braembl.org.au/gt-scan/ 64) and CRISPick (https://portals.broadinstitute.org/gppx/crispick/ public65) were used to design guide sequences targeting the loci of interest. .. The designed sgRNA were cloned into Expressing:Article Title: Hypoxia-induced CTCF mediates alternative splicing via coupling chromatin looping and RNA Pol II pause to promote EMT in breast cancer. Article Snippet: Next, for rescue experiments, CTCF depleted cells were transfected with COL5A1exon64A or COL5A1exon64B transcript overexpression plasmid using Lipofectamine 2000 reagent (Invitrogen, 11668019) as per the manufacturer’s instructions. sgRNA designing and cloning in dCas9-DNMT3A expression vector and cell transfections GT-Scan web-tool (http://gt-scan.braembl.org.au/gt-scan/ 64) and CRISPick (https://portals.broadinstitute.org/gppx/crispick/ public65) were used to design guide sequences targeting the loci of interest. .. The designed sgRNA were cloned into Control:Article Title: Hypoxia-induced CTCF mediates alternative splicing via coupling chromatin looping and RNA Pol II pause to promote EMT in breast cancer. Article Snippet: The designed sgRNA were cloned into dCas9_DNMT3A (Addgene #74407) expression vectors as described previously40,86 using BpiI/BbsI (Fermentas, Cat No. ER1012). .. Additionally, Addgene #71830 plasmid having non-targeting (NT) control guide RNAs (sgcontrol) was used as a control for |
![CTCF is required for optimal GLUT3 expression under hypoxia. A) mRNA expression of glycolysis genes in sh_control under normoxia and hypoxia and sh_CTCF under hypoxia in MCF7 cells inferred from CTCF depletion RNA-seq B) genome browser view of SLC2A3 loci of CTCF-ChIP-seq and RNA-seq under normoxia and hypoxia and of RNA-seq in shcontrol and shCTCF under hypoxia in MCF7 cells C) UMAP plot of breast epithelial cancerous cell populations stratified as continuous hypoxic state using Buffa score highlighting CTCF expression and SLC2A3 expression D) Schematic representation of targeting the CTCF motif present in the SLC2A3/GLUT3 promoter region by <t>dCas9-DNMT3A</t> with specific sgRNA against CTCF to maintain methylation and suppress CTCF occupancy E-G) E and F) MeDIP-qPCR and CTCF-ChIP-qPCR on GLUT3 promoter E) MCF7 and F) MDA-MB-231 (G) immunoblot of GLUT3 in MCF7 and MDA-MB-231cells transfected with dCas9-DNMT3A-sgCTCF in comparison to the sgcontrol under hypoxia (H) Schematic showing hypoxia-driven epigenetic and transcriptional regulation of GLUT3 expression in breast cancer. Data represent three technical replicates from pooled samples. Data are mean ± SEM, statistical significance was determined using unpaired, two-tailed Welch’s Two-Sample t-test (A), Co-expression was assessed using Fisher’s exact test (odds ratio [OR] = 1.80, p < 2.2 × 10⁻¹⁶) (C), unpaired two-tailed Student’s t-tests (F and G), *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.](https://bio-rxiv-images-cdn.bioz.com/dois_ending_with_00/10__64898_slash_2026__10__27__762200/10__64898_slash_2026__10__27__762200___F2.large.jpg)